Skip to main content
. 2018 Dec 15;12(3):426–431. doi: 10.1016/j.tranon.2018.11.015

Figure 3.

Figure 3

Dynamic changes of mutations and mutation abundance tested by NGS during treatment in four patients. During the treatment of cetuximab, the abundance of mutations detected in the ctDNA at the baseline showed a downward trend with the treatment process. The corresponding imaging to the blood collection time showed that new drug-resistant mutations were detected in blood in advance of imaging development.